OncoMatch/Clinical Trials/NCT06313970

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

Is NCT06313970 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including QL1706 and Nab-paclitaxel for pancreatic cancer.

Phase 2RecruitingFudan UniversityNCT06313970Data as of May 2026

Treatment: QL1706 · Nab-paclitaxel · Gemcitabine · Bevacizumab — This is a multicenter, open-label, exploratory study to evaluate the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine with or without bevacizumab as first-line treatment in patients with unresectable locally advanced or metastatic pancreatic cancer

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: immune checkpoint inhibitor

Patients who receive any prior treatments targeting the mechanism of tumor immunity, such as immune checkpoint blockades, immune checkpoint agonists, immune cell therapy, etc.

Lab requirements

Blood counts

adequate major organ function (no medication for blood component, cell growth factor correction therapy is allowed within 14 days before randomization)

Kidney function

adequate major organ function (no medication for blood component, cell growth factor correction therapy is allowed within 14 days before randomization)

Liver function

adequate major organ function (no medication for blood component, cell growth factor correction therapy is allowed within 14 days before randomization)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify